Genetic counseling for hereditary cancers: Not everybody’s cup of tea!

Rekha Gupta, Satyajeet Soni, Hemant Malhotra
{"title":"Genetic counseling for hereditary cancers: Not everybody’s cup of tea!","authors":"Rekha Gupta, Satyajeet Soni, Hemant Malhotra","doi":"10.4103/crst.crst_271_23","DOIUrl":null,"url":null,"abstract":"We read with deep interest the review article published in the previous issue of Cancer Research Statistics and Treatment authored by Ulhaq et al.[1] We feel that this manuscript is of utmost importance for practicing oncologists and the journal needs to be congratulated for selecting this for publication to highlight this issue. After more than three decades of practicing oncology in the country, the senior writer of this letter is acutely aware of the lack of knowledge among treating clinicians and the extreme dearth of trained genetic counselors. Hereditary cancer contributes 5–10% of the overall cancer incidence. Early diagnosis and treatment are the most successful tools in cancer management for a higher survival rate. This principle can be applied to hereditary cancer families by identifying high-risk individuals and putting them on surveillance. Genetic counseling is the first step in this process. Pivotal steps have been discussed in the article.[1] Developing genetic counseling units with specialization in oncology is an important step towards generating awareness about hereditary cancer syndromes. As multiple family members are at risk of developing cancer, multiple lives can be saved by providing surveillance and prevention to such families. Counseling and offering genetic testing based on the next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) techniques is at the heart of this concept of prevention, early diagnosis, and treatment. A few important issues were not highlighted in this article.[1] One important issue in the Indian scenario is pre-symptomatic carrier detection in a young person and marriage-related issues,[2] and the reproductive implications of this diagnosis. Such individuals carry a lifetime risk of cancer, and their offspring will harbor the mutation in 50% of cases. Genetic counseling must be offered to such reproductive couples. Preimplantation genetic diagnosis (PGD) can be offered to couples who are conceiving through in vitro fertilization (IVF). The second important issue is the psychological stress of receiving a pre-symptomatic diagnosis. These newly diagnosed pre-symptomatic carriers are young individuals who are on the verge of their careers and starting their reproductive lives. We need a team of support groups, counselors, and psychologists to take care of the pre-symptomatic diagnosis hurdles amidst job security, insurance policy, etc. The authors, even though they claim to have written an India-specific article, have missed out on at least three major publications in the field from India which significantly add to the knowledge on the subject.[3-5] The cost of testing and surveillance also needs to be considered by the individual patient/person. Now, with a large industrial house with deep pockets, entering the field of genetic testing and promising comprehensive genetic profiling at less than `15,000, a whole set of new and unknown issues are bound to arise, and technical awareness and expertise will be desperately needed to tackle this. Trained genetic counselors are lacking in oncology units. Pretest and posttest counseling is extremely important. Often, we deal with a dissatisfied patient and/or their family when confronted with a genetic abnormality labeled as a variant of uncertain significance (VOUS) when adequate pretest counseling is not done. VOUS’ are not actionable. Medical/surgical intervention to prevent cancer cannot be offered. Family members are screened as per their risk status in the pedigree analysis. VOUS variants may, however, be reclassified based on the results of testing of other affected and unaffected family members. Reanalysis of data can also be offered as new information is added to the literature with time. If a pathogenic or likely pathogenic variant is identified in the report, it is actionable, and screening of family members can be offered. Family members who become carriers of the variant need psychological support and need to be put on cancer surveillance. Individuals who test negative are relieved. They can act as positive pillars of the family. We are lucky to have a superbly trained medical geneticist and a full-fledged department of medical genetics at our center. However, the situation is not so rosy at most centers. We strongly advocate that a trained genetic counselor be available at all large comprehensive cancer treatment centers. Till this happens, treating oncologists will have to pull up their socks, get trained in the field, and take up the responsibility of genetic counseling of their patients. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"278 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Research, Statistics, and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/crst.crst_271_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

Abstract

We read with deep interest the review article published in the previous issue of Cancer Research Statistics and Treatment authored by Ulhaq et al.[1] We feel that this manuscript is of utmost importance for practicing oncologists and the journal needs to be congratulated for selecting this for publication to highlight this issue. After more than three decades of practicing oncology in the country, the senior writer of this letter is acutely aware of the lack of knowledge among treating clinicians and the extreme dearth of trained genetic counselors. Hereditary cancer contributes 5–10% of the overall cancer incidence. Early diagnosis and treatment are the most successful tools in cancer management for a higher survival rate. This principle can be applied to hereditary cancer families by identifying high-risk individuals and putting them on surveillance. Genetic counseling is the first step in this process. Pivotal steps have been discussed in the article.[1] Developing genetic counseling units with specialization in oncology is an important step towards generating awareness about hereditary cancer syndromes. As multiple family members are at risk of developing cancer, multiple lives can be saved by providing surveillance and prevention to such families. Counseling and offering genetic testing based on the next-generation sequencing (NGS) and multiplex ligation-dependent probe amplification (MLPA) techniques is at the heart of this concept of prevention, early diagnosis, and treatment. A few important issues were not highlighted in this article.[1] One important issue in the Indian scenario is pre-symptomatic carrier detection in a young person and marriage-related issues,[2] and the reproductive implications of this diagnosis. Such individuals carry a lifetime risk of cancer, and their offspring will harbor the mutation in 50% of cases. Genetic counseling must be offered to such reproductive couples. Preimplantation genetic diagnosis (PGD) can be offered to couples who are conceiving through in vitro fertilization (IVF). The second important issue is the psychological stress of receiving a pre-symptomatic diagnosis. These newly diagnosed pre-symptomatic carriers are young individuals who are on the verge of their careers and starting their reproductive lives. We need a team of support groups, counselors, and psychologists to take care of the pre-symptomatic diagnosis hurdles amidst job security, insurance policy, etc. The authors, even though they claim to have written an India-specific article, have missed out on at least three major publications in the field from India which significantly add to the knowledge on the subject.[3-5] The cost of testing and surveillance also needs to be considered by the individual patient/person. Now, with a large industrial house with deep pockets, entering the field of genetic testing and promising comprehensive genetic profiling at less than `15,000, a whole set of new and unknown issues are bound to arise, and technical awareness and expertise will be desperately needed to tackle this. Trained genetic counselors are lacking in oncology units. Pretest and posttest counseling is extremely important. Often, we deal with a dissatisfied patient and/or their family when confronted with a genetic abnormality labeled as a variant of uncertain significance (VOUS) when adequate pretest counseling is not done. VOUS’ are not actionable. Medical/surgical intervention to prevent cancer cannot be offered. Family members are screened as per their risk status in the pedigree analysis. VOUS variants may, however, be reclassified based on the results of testing of other affected and unaffected family members. Reanalysis of data can also be offered as new information is added to the literature with time. If a pathogenic or likely pathogenic variant is identified in the report, it is actionable, and screening of family members can be offered. Family members who become carriers of the variant need psychological support and need to be put on cancer surveillance. Individuals who test negative are relieved. They can act as positive pillars of the family. We are lucky to have a superbly trained medical geneticist and a full-fledged department of medical genetics at our center. However, the situation is not so rosy at most centers. We strongly advocate that a trained genetic counselor be available at all large comprehensive cancer treatment centers. Till this happens, treating oncologists will have to pull up their socks, get trained in the field, and take up the responsibility of genetic counseling of their patients. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
遗传性癌症的遗传咨询:不是每个人的茶!
我们怀着浓厚的兴趣阅读了Ulhaq等人在上期《癌症研究统计与治疗》(Cancer Research Statistics and Treatment)上发表的综述文章。[1]我们认为这篇论文对肿瘤执业医师来说是极其重要的,我们需要祝贺该杂志选择发表这篇文章来突出这一问题。在国内从事肿瘤治疗三十多年后,这封信的资深作者敏锐地意识到治疗临床医生缺乏知识,训练有素的遗传咨询师极度缺乏。遗传性癌症占癌症总发病率的5-10%。早期诊断和治疗是提高生存率的最成功的癌症管理工具。这一原则可以通过识别高风险个体并对其进行监视来应用于遗传性癌症家族。遗传咨询是这个过程的第一步。本文讨论了关键步骤。[1]发展具有肿瘤学专业的遗传咨询单位是提高对遗传性癌症综合征认识的重要一步。由于多个家庭成员都有患癌症的危险,因此,通过对这些家庭进行监测和预防,可以挽救多个生命。咨询和提供基于下一代测序(NGS)和多重连接依赖探针扩增(MLPA)技术的基因检测是这一预防、早期诊断和治疗概念的核心。本文没有强调几个重要问题。[1]在印度的情况下,一个重要的问题是在年轻人中发现症状前的携带者和与婚姻相关的问题,[2]以及这种诊断对生殖的影响。这样的人一生都有患癌症的风险,他们的后代在50%的情况下会携带这种突变。必须向这些生育的夫妇提供遗传咨询。胚胎植入前遗传学诊断(PGD)可以提供给通过体外受精(IVF)怀孕的夫妇。第二个重要的问题是接受症状前诊断的心理压力。这些新诊断的症状前携带者是处于职业生涯边缘并开始生育生活的年轻人。我们需要一个由支持小组、咨询师和心理学家组成的团队来处理在工作保障、保险政策等方面的症状前诊断障碍。尽管作者声称他们写的是一篇针对印度的文章,但他们至少错过了印度在该领域的三个主要出版物,这些出版物大大增加了对该主题的了解。[3-5]检测和监测的成本也需要按患者个体来考虑。现在,随着一家财力雄厚的大型工业公司,以低于1.5万美元的价格进入基因检测和有前景的全面基因分析领域,一系列新的和未知的问题必然会出现,迫切需要技术意识和专业知识来解决这个问题。肿瘤科缺乏训练有素的遗传咨询师。测试前和测试后的咨询是非常重要的。通常情况下,我们处理不满意的病人和/或他们的家人,当面对遗传异常标记为不确定意义的变异(VOUS),而没有做充分的预检测咨询。保证书是不可操作的。不能提供预防癌症的医疗/手术干预。在系谱分析中,根据家庭成员的风险状况进行筛查。然而,VOUS变异可以根据其他受影响和未受影响的家庭成员的检测结果重新分类。随着时间的推移,新的信息被添加到文献中,也可以提供数据的重新分析。如果在报告中确定了致病性或可能致病性变异,则可采取行动,并可提供家庭成员筛查。成为变异携带者的家庭成员需要心理支持,并需要进行癌症监测。测试呈阴性的人就放心了。他们可以成为家庭的积极支柱。我们很幸运,我们中心有一位训练有素的医学遗传学家和一个成熟的医学遗传学部门。然而,大多数中心的情况并非如此乐观。我们强烈建议在所有大型综合癌症治疗中心配备训练有素的遗传咨询师。在此之前,治疗肿瘤的医生必须振作起来,接受这一领域的培训,并承担起为患者提供遗传咨询的责任。财政支持及赞助无。利益冲突没有利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.00
自引率
0.00%
发文量
142
审稿时长
13 weeks
期刊最新文献
Translation and validation of the Hindi, Marathi, and Bangla versions of the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire: Anal Cancer (QLQ-ANL27) module: A prospective cohort study Translation and validation of the Hindi, Marathi, and Bangla versions of the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire: Anal Cancer (QLQ-ANL27) module: A prospective cohort study The potential for further exploration of extramedullary spinal tumors in Iranian patients. Carcinoma cervix with scalp metastasis: An unusual case report Caregiving: A loving burden
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1